News for SCPS Stock

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit Scopus BioPharma Provides Update Following Annual Meeting of Stockholders DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the Company Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card Dr. Morris C. Laster Issues An Open Letter To Scopus BioPharma Inc. Stockholders In Connection With Upcoming Annual Meeting Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders Scopus BioPharma to Present at the LD Micro Main Event Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board Scopus BioPharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting Scopus BioPharma Launches Duet Therapeutics Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate Scopus BioPharma Finalizes Arrangements for Submission of IND Package Scopus BioPharma Announces Closing of Underwriters' Over-Allotment Option in Full Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million Scopus BioPharma Announces Closing of $9 Million Follow-On Public Offering Scopus BioPharma Announces Exchange Offer Scopus BioPharma Announces Pricing of $9 Million Follow-On Public Offering Scopus BioPharma Announces Completion of Clinical Lot Manufacture Scopus BioPharma Announces Appointment of Additional Directors Scopus BioPharma Announces Closing of Initial Public Offering